Melanotan II Research Overview: Melanocortin Agonism, Tanning, and Sexual Function
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Melanotan II (MT-II) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It was developed at the University of Arizona in the 1980s as part of a research program to develop a tanning agent that could protect against UV-induced skin cancer. MT-II acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R, MC5R), producing a broad range of physiological effects.
Mechanism of Action
MC1R (melanocortin-1 receptor): Expressed on melanocytes in the skin. MC1R activation stimulates melanin production (both eumelanin and phaeomelanin), producing skin darkening (tanning) without UV exposure.
MC3R (melanocortin-3 receptor): Expressed in the hypothalamus and limbic system. MC3R activation modulates energy homeostasis and appetite.
MC4R (melanocortin-4 receptor): Expressed throughout the CNS. MC4R activation suppresses appetite, increases energy expenditure, and mediates sexual arousal. MC4R is the primary receptor responsible for MT-II's sexual effects.
MC5R (melanocortin-5 receptor): Expressed in exocrine glands and peripheral tissues. MC5R activation influences sebaceous gland function and exocrine secretion.
Tanning Research
The original research goal for Melanotan II was to develop a photoprotective tanning agent. Research demonstrated that MT-II produced dose-dependent skin darkening in human subjects without UV exposure. The tanning effect is mediated through MC1R activation, which stimulates melanocytes to produce eumelanin (brown/black pigment).
Comparison with Afamelanotide: Afamelanotide (Scenesse) is a more selective MC1R agonist derived from MT-II research that received European approval for erythropoietic protoporphyria (EPP). This demonstrates the clinical translation potential of the MT-II research program.
Sexual Function Research
MT-II's sexual effects were discovered serendipitously during early clinical trials when subjects reported spontaneous erections. This led to the development of PT-141 (bremelanotide) as a more selective compound for sexual dysfunction research.
Mechanism: MT-II activates MC4R in the hypothalamus, triggering dopamine release in the mesolimbic pathway and activating oxytocin neurons in the paraventricular nucleus — both pathways involved in sexual arousal.
Clinical trials: Early Phase 1/2 trials demonstrated that MT-II produced erections in men with psychogenic erectile dysfunction, including those who had not responded to PDE5 inhibitors.
Appetite Suppression Research
MT-II potently suppresses appetite through MC4R activation in the hypothalamus. Research in rodent models has shown that MT-II administration reduces food intake by 40-60% and promotes weight loss. This appetite-suppressing effect is a significant side effect in human subjects.
Comparison with PT-141
| Parameter | Melanotan II | PT-141 (Bremelanotide) | |-----------|-------------|----------------------| | Receptor selectivity | Non-selective (MC1-5) | Selective (MC3R, MC4R) | | Tanning effect | Strong (MC1R) | Minimal | | Sexual function | Yes (MC4R) | Yes (MC4R) - primary effect | | Appetite suppression | Strong | Moderate | | FDA status | Not approved | Approved (HSDD, 2019) | | Nausea | Common | Moderate |
Summary
Melanotan II served as the foundational research compound for the melanocortin receptor field, directly leading to the development of PT-141 (FDA-approved for HSDD) and afamelanotide (EU-approved for EPP). Its non-selective receptor profile makes it a valuable research tool for studying the full spectrum of melanocortin receptor biology.
See Also: PT-141 (Bremelanotide) Research Overview | Peptide Research Glossary: Key Terms and Definitions
Was this article helpful?
Click a star to rate